DelNova, a drug development company, was founded with the mission to advance muscle recovery through innovative therapies. The company focuses on leveraging advances in drug delivery technology, specifically developing treatments that utilize an anticholinesterase class of drugs. These drugs work by indirectly increasing the neurotransmitter deficit caused by botulinum toxin, thereby accelerating muscle recovery. DelNova's primary product, ReViVox®, is aimed at both therapeutic and aesthetic markets, addressing a significant need for effective muscle recovery solutions.
DelNova has assembled a team of senior management, a board of directors, and scientific advisors who are experts in their fields. The company has garnered attention for its novel approach and has made significant strides in its pipeline development. Notable achievements include the successful demonstration of ReViVox®'s mechanism of action and its potential applications. DelNova's impact lies in its potential to revolutionize muscle recovery treatments, offering new hope to patients affected by conditions requiring botulinum toxin therapy.
